<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8062">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01690104</url>
  </required_header>
  <id_info>
    <org_study_id>Rifa-BP</org_study_id>
    <secondary_id>2011-005522-22</secondary_id>
    <nct_id>NCT01690104</nct_id>
  </id_info>
  <brief_title>The Effect of PXR Activation on Blood Pressure Regulation</brief_title>
  <official_title>The Effect of PXR Activation on Blood Pressure Regulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <authority>Finland: Finnish Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are investigating the effects of pregnane X receptor (PXR) activation on the regulation
      of blood pressure in healthy volunteers. Rifampicin (an antibiotic and also an efficient PXR
      activator) and placebo will be given for a week to volunteers and blood pressure is measured
      24 hours using an ambulatory blood pressure monitor. Blood pressure regulating hormones will
      be measured in blood. Our hypothesis is that PXR is involved in the regulation of blood
      pressure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Systolic ambulatory blood pressure</measure>
    <time_frame>On day 8 of each arm</time_frame>
    <safety_issue>No</safety_issue>
    <description>Systolic blood pressure measured with ambulatory blood pressure monitor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic ambulatory blood pressure</measure>
    <time_frame>On day 8 of each arm</time_frame>
    <safety_issue>No</safety_issue>
    <description>Diastolic blood pressure measured with ambulatory blood pressure monitor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic blood pressure</measure>
    <time_frame>On day 9 of each arm</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse (ambulatory)</measure>
    <time_frame>On day 8 of each arm</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma renin activity</measure>
    <time_frame>On day 9 of each arm</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum aldosterone</measure>
    <time_frame>On day 9 of each arm</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Blood Pressure Regulation</condition>
  <arm_group>
    <arm_group_label>Rifampicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rifampicin 600 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <arm_group_label>Rifampicin</arm_group_label>
    <other_name>Rimapen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  BMI 19-30 kg/m2

          -  Age 18-40 years

          -  Systolic blood pressure 95 - 140 mmHg

        Exclusion Criteria:

          -  Any continuous medication

          -  Any significant medical condition as judged by the study physician

          -  Diastolic blood pressure over 90 mmHg

          -  Sensitivity to rifampicin

          -  Pregnancy and lactation

          -  Difficult venipuncture

          -  Abuse of alcohol or medications, or drug use.

          -  Participation in other trial with medications in previous 30 days
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janne Hukkanen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janne Hukkanen, MD, PhD</last_name>
    <phone>35883156212</phone>
    <email>janne.hukkanen@oulu.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janne Hukkanen, MD, PhD</last_name>
      <phone>35883156212</phone>
      <email>janne.hukkanen@oulu.fi</email>
    </contact>
    <investigator>
      <last_name>Janne Hukkanen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 17, 2012</lastchanged_date>
  <firstreceived_date>September 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rifampicin</keyword>
  <keyword>pregnane X receptor</keyword>
  <keyword>blood pressure</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
